Navigation Links
Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
Date:12/22/2011

GREENWOOD VILLAGE, Colo., Dec. 22, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced notification of the granting of a Canadian patent with broad claims directed to: "METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM". The protected compositions contain either DA-DKP, a cyclic dipeptide diketopiperazine, which is the active ingredient of Ampion™, but also extend to many other diketopiperizines.

Dr. David Bar-Or, Ampio's Chief Scientific Officer, noted "The patent also includes claims for these compositions that target clinical treatments for inflammation and inflammatory diseases and conditions, such as disease or condition is acute respiratory distress syndrome, an allergy, arthritis, asthma, bronchitis, a cancer, a cardiovascular disease, Crohn's disease, cystic fibrosis, emphysema, endocarditis, gastritis, gastrointestinal ulceration, inflammatory bowel disease, ischemia, ischemia reperfusion, multiple organ dysfunction syndrome, myocardial infarction, a neoplastic disease, nephritis, pain, pancreatitis, psoriasis, a respiratory infection, sepsis, shock or ulcerative colitis."

Dr. Bar-Or further noted "This patent complements the already extensive and robust portfolio of worldwide issued patents for Ampion™. The mechanism of action of Ampion™, an innate human biological small molecular weight compound, is unique as it not only inhibits the early activation of memory T cells but also affects an upstream event in inflammation by tightening vascular permeability among other effects".

"We believe that multiple inflammatory conditions might benefit from this biological drug" added Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, "and the compa
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
2. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
3. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
4. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
5. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
6. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
7. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
8. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
9. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
10. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
11. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 VG Life ... therapies for autoimmune and infectious diseases, announced that ... issued an important new composition of matter patent ... the targeting of CLIP. U.S. ... underlying VG Life Sciences, VG1177, a synthetic peptide ...
(Date:3/2/2015)... Outside GC, the leading provider of ... of Debbie Casey as a member of the firm, ... , Debbie has spent over 20 years ... Medical Care North America in both legal and business ... work with Outside GC’s growing list of healthcare clients, ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine” or ... a fraudulent press release disseminated this morning by PR ... Immunovaccine. This press release states that Immunovaccine has entered ... The press release did not originate from Immunovaccine and ... the press release. Please note that all official ...
(Date:2/27/2015)... A paper published today, " Financing ... in Science Translational Medicine, demonstrates the ... the risk associated with investing in the treatment ... of funding for developing so-called "orphan" drugs. ... between scientists at the National Center for Advancing ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Outside GC Expands Healthcare Team 2Immunovaccine Disclaims Hoax Press Release 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4
... Md., Dec. 19 Dr. Joseph,Corriveau was recently ... Chemical Biological Center (ECBC). With this appointment, Dr.,Corriveau ... of the SES,serve in key positions just below ... the appointees and the federal work force., ...
... LifeCell,Corporation (Nasdaq: LIFC ), today announced ... 2008 financial guidance on Monday, January,7, 2008 at ... Executive,Officer, will host a conference call at 10:00 ... revenues and expected financial performance,for 2008., The ...
... Have Been Resolved; Remaining Issues Pertain to ... Third-party Manufacturing Facility Company Expects to Resolve ... Mass., Dec. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ... from the U.S. Food and Drug Administration (FDA) for,VALSTAR(TM) ...
Cached Biology Technology:Dr. Joseph L. Corriveau Appointed Director of Research and Technology 2LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern 2Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 2Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 3Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 4
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris Biometrics in ... US, Canada , Japan ... , Middle East , and ... for the period 2013 through 2020. Also, a seven-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... prediction program by computer scientists at Washington University in ... beginnings of gene transcription start sites and where the ... the gene. , The modification to the gene prediction ... of computer science at Washington University in St. Louis, ...
... effects of climate change on rainforests is being investigated ... shape of epiphytes ('air-plants' which grow on other plants) ... have been affected by climate change over the last ... bromeliads, Monica Mejia-Chang from Professor Howard Griffiths' lab in ...
... human genes has begun at the European Molecular ... the MitoCheck consortium that includes 10 other institutes ... human genes, one-by-one, to find those involved in ... of how cell division is regulated. , The ...
Cached Biology News:Modification of program enables prediction of gene transcription 2Modification of program enables prediction of gene transcription 3Hunt for human genes involved in cell division under way 2
... the major proteolytic system in the ... catalyzes the selective degradation of short-lived ... of proteins with abnormal conformation (Hershko ... critical protease in this pathway is ...
... Exiqons LNA technology enables sensitive, fast and ... intact chromosomes. Short hybridisation time ... cells and chromosome spreads Multiplex capability ... probes Probes available with ...
... rat adult and fetal tissue, ... * T75 plated cells $750.00, ... This product requires Celprogen Stem ... and extracellular matrix, * E55007-08-T25 ...
... Bacterial DNA Isolation Kit provides a rapid ... genomic DNA from the various bacterial species ... the isolation of genomic DNA from both ... milk samples. ,Purification is based on ...
Biology Products: